Vivanate Rompharm,1 mg/ml 3 ml

Bone resorption inhibitor, nitrogen-containing bisphosphonate. It has a selective effect on bone tissue, which is due to its high affinity for hydroxyapatite, which constitutes the mineral matrix of bone. Ibandronic acid suppresses bone resorption and has no direct effect on bone formation.

Ibandronic acid prevents bone destruction caused by cessation of glandular function, retinoids, tumors and tumor extracts in vivo.

In postmenopausal women, it reduces the increased rate of bone renewal to reproductive age levels, resulting in a progressive increase in bone mass.

Ibandronic acid prevents the development of new and reduces the growth of existing bone metastases. It has a dose-dependent inhibitory effect on tumor osteolysis.

Indications

Postmenopausal osteoporosis to prevent fractures.

Metastatic bone lesions to reduce the risk of hypercalcemia, pathological fractures, to reduce pain, reduce the need for radiation therapy for pain syndrome and the threat of fractures.

Hypercalcemia in malignant neoplasms.

Active ingredient

How to take, the dosage

It is administered orally or intravenously.

The dose and route of administration depend on the indication and clinical situation.

Interaction

Special Instructions

With caution use in patients with hypersensitivity to other bisphosphonates.

During treatment, renal function and plasma levels of calcium, phosphorus and magnesium should be monitored. It is recommended to avoid excessive hydration in patients with circulatory insufficiency.

Avoid intra-arterial administration.

Products containing calcium and other polyvalent cations (e.g., aluminum, magnesium, iron), including milk and solid foods, may interfere with absorption of ibandronic acid (these should not be consumed before 30 minutes after oral administration of the medication).

Contraindications

In oral and intravenous administration: hypocalcemia, severe renal impairment (CK<30 ml/min), esophageal disorders resulting in delayed emptying such as stricture or achalasia (for oral administration), pregnancy, lactation (breastfeeding), childhood and adolescence below 18 years of age, hypersensitivity to ibandronic acid.

In oral administration: lesions of the esophagus leading to delayed emptying, such as stricture or achalasia; inability to remain seated or standing for 60 minutes.

Side effects

Skin and subcutaneous tissue: often – rash.

Allergic reactions: rarely – angioedema, facial edema, urticaria.

Muscular system: often – arthralgia, myalgia, pain in the extremities, osteoarthritis, back pain, musculoskeletal pain; infrequently – bone pain; rarely – atypical intercostal and diaphyseal fractures of the femur (typical for bisphosphonates class); very rare – osteonecrosis of the jaw.

Visually: rarely – inflammatory eye disease.

The body in general: often – flu-like syndrome, weakness; infrequently – asthenia.

Others: frequent – nasopharyngitis, cystitis, urinary tract infections, bronchitis, upper respiratory tract infections, arterial hypertension, hypercholesterolemia; infrequent – reactions in the injection site, phlebitis, thrombophlebitis; rarely – hypersensitivity reactions; with intravenous administration a transient decrease in serum calcium levels may occur.

Pregnancy use